No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 261 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi November 23, 2020 Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... November 14, 2024 FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease February 1, 2022 Load more HOT NEWS These Triplets Were Tired Of Being Mistaken For Each Other. Their... Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer
